Collegium Pharmaceutical
COLL
72 hedge funds and large institutions have $306M invested in Collegium Pharmaceutical in 2016 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 27 increasing their positions, 15 reducing their positions, and 10 closing their positions.
80% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 15
76% more capital invested
Capital invested by funds: $173M → $306M (+$132M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1% less funds holding
Funds holding: 73 → 72 (-1)
10% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 10
94% less call options, than puts
Call options by funds: $58K | Put options by funds: $963K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Cadian Capital Management
New York
|
+$5.7M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$4.89M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$4.78M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$3.92M |
| 5 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
+$1.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$3.34M |
| 2 |
Bank of New York Mellon
New York
|
-$2.63M |
| 3 |
AII
AGF Investments Inc
Toronto,
Ontario, Canada
|
-$1.32M |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.2M |
| 5 |
TA
Tamarack Advisers
Carlsbad,
California
|
-$1.13M |
COLL Hedge Fund Activity: Q3 2016 in Review
72 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Collegium Pharmaceutical (COLL) for Q3 2016, worth a combined $306M — up 76% from $173M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of COLL and 9 opened new positions — a net loss of 1 holder — while 15 trimmed existing stakes and 27 added.
The largest buyer was Cadian Capital Management, opening a new position worth an estimated $5.7M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $3.34M sold.
- 72 institutional investors held Collegium Pharmaceutical (COLL) as of Q3 2016, down from 73 in Q2 2016.
- Funds reported $306M of Collegium Pharmaceutical stock for Q3 2016, up 76% quarter-over-quarter.
- 9 funds opened new Collegium Pharmaceutical positions in Q3 2016 and 10 closed out, a net change of -1 holder.
- The largest Collegium Pharmaceutical buyer in Q3 2016 was Cadian Capital Management, an estimated $5.7M added.
- The largest Collegium Pharmaceutical seller in Q3 2016 was EcoR1 Capital, an estimated $3.34M sold.
Based on aggregated 13F filings for Q3 2016.